Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019240 · ClinicalTrials.gov registry record · Phase 2
Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019240: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019240 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019240, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Herpesvirus is found in Kaposi's sarcoma lesions in most patients; it is therefore possible that the herpesvirus has a role in causing Kaposi's sarcoma. Cidofovir is an antiviral drug that acts against many types of herpesvirus, and may be an effective treatment for Kaposi's sarcoma. PURPOSE: Phase II trial to study the effectiveness of cidofovir in treating patients with Kaposi's sarcoma with or without HIV infection.
Interventions
- DRUG cidofovir
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019240
The ClinicalTrials.gov registry entry for NCT00019240 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cidofovir is the first listed.
NCT00019240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019240 about?
NCT00019240 is a clinical study titled "Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection". RATIONALE: Herpesvirus is found in Kaposi's sarcoma lesions in most patients; it is therefore possible that the herpesvirus has a role in causing Kaposi's sarcoma. Cidofovir is an antiviral drug that acts against many types of herpesvirus, and may be an effective treatment for Kaposi's sarcoma. PUR...
What is the current status of trial NCT00019240?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-11. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00019240?
The interventions under investigation include: cidofovir (DRUG).
Who is sponsoring clinical trial NCT00019240?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.